Tag: pancreatic cancer
-
Belviq Recall Aftermath: Further FDA Action in 2021 Means There Will Be No Belviq Generic Drugs
Belviq Was Withdrawn From Market Due to Increased Risk of Certain Cancers: Pancreatic, Colon, Rectal, And Lung (Posted by Tom Lamb at Drug Injury Watch) Recently we found some further FDA action…
-
Zantac Recall In April 2020 Comes 7 Months After The Zantac FDA Warning In September 2019
Level Of Chemical NDMA In Zantac Pills Can Cause Cancers: Pancreatic, Stomach, Colon, Rectal, Bladder, Kidney (Posted by Tom Lamb at DrugInjuryWatch.com) On April 1, 2020, the FDA announced that it was…
-
Belviq Lawsuits: Cancers Associated With Belviq Diet Drug Recall Include Pancreatic, Colorectal, Lung
Patients On Belviq Developing Cancer File Lawsuits Against Responsible Drug Company For Failure To Warn (Posted by Tom Lamb at DrugInjuryWatch.com) The Belviq recall was announced in February 2020 after the FDA…
-
Belviq Recall: FDA Warning Cancer Risks Of Diet Drug Belviq Outweigh Benefits — February 2020
Excess Cases Of Pancreatic Cancer, Colon Cancer, Rectal Cancer, And Lung Cancer Observed In Belviq Safety Clinical Trial (Posted by Tom Lamb at DrugInjuryWatch.com) On February 13, 2020 the FDA requested Eisai…
-
Zantac FDA Warning In September 2019 Leads To Lawsuits For Patients Diagnosed With Cancer
Cases Involve Stomach, Colon, Rectal, Bladder, Kidney, And Pancreatic Cancers Diagnosed After Taking Zantac (Posted by Tom Lamb at DrugInjuryWatch.com) Zantac cancer lawsuits are being filed for patients diagnosed with certain types…
-
Pancreatic Cancer Associated With Use Of Diabetes Medicines In DPP-4 Inhibitor Drug Class
Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study (Posted by Tom Lamb at DrugInjuryWatch.com) Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated…
-
Diet Drug Saxenda May Increase Pancreatic Cancer Risks For Patients Only Wanting Weight Loss
Saxenda Dose Contains Twice As Much Liraglutide As Diabetes Medicine Victoza, Also Linked To Malignancy In Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com) In 2014, the FDA approved Saxenda (liraglutide) for the…
-
There Is Continuing Concern About Whether Victoza Is Associated With Pancreatic Cancer As A Possible Side Effect
The FDA Briefing Materials For A June 2017 Advisory Committee Meeting On Victoza Include A Discussion Of This Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com) On June 20, 2017 there will…
-
Diabetes Drugs Bydureon And Victoza: Thyroid Cancer Label Change In March 2015 Comes Without Much Notice
FDA Letters To AstraZeneca And Novo Nordisk Approve Addition Of Information About Increased Risk For Medullary Thyroid Carcinoma (MTC) (Posted by Tom Lamb at DrugInjuryWatch.com) The diabetes drugs Bydureon (exenatide extended-release) for injectable suspension and Victoza (liraglutide…
-
Pancreatic Cancer As A Side Effect Of Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza
Health Canada Currently Conducting Epidemiological Study Of These Incretin-Based Type 2 Diabetes Medications To Assess This Potential Drug Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com)From the October 2014 edition of the Canadian Adverse Reaction Newsletter we…